

MIFAMURTIDE (Mepact) in combination with MAP and AMM

INDICATION (ICD10) C41

1. Adjuvant following resection, high-grade resectable, non-metastatic osteosarcoma in young adults (up to 30 years old). (TA235)

REGIMEN

Weeks 1 to 12

Days 1 and 4 Premedication 30 minutes prior to infusion:

Paracetamol 1000mg IV

MIFAMURTIDE 2mg/m² in 100ml sodium chloride 0.9% IV infusion over 60 minutes

Weeks 13 to 36

Day 1 Premedication 30 minutes prior to infusion:

Paracetamol 1000mg IV

MIFAMURTIDE 2mg/m² in 100ml sodium chloride 0.9% IV infusion over 60 minutes

Must leave at least 72 hours between doses of mifamurtide.

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 7 days for 36 weeks (total 48 doses)

ANTI-EMETICS

Moderate emetic risk (avoid steroids)

CONCURRENT MEDICATION REQUIRED

Mifamurtide	Ensure premedication given before mifamurtide.
-------------	--

EXTRAVASATION AND TYPE OF LINE / FILTERS

Mifamurtide – non vesicant

Peripheral or central line

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x 10⁹/L administration is count independent

Platelets x 10⁹/L administration is count independent

Baseline weight and every cycle

MAIN TOXICITIES AND ADVERSE REACTIONS

Mifamurtide	Tiredness and flu like symptoms initially, can be treated with paracetamol. Reports of increased ototoxicity with concomitant cisplatin requires careful assessment if combined. Mild moderate tachycardia, hypertension, hypotension. Dyspnoea. Musculoskeletal pain.
-------------	--

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS
(not exhaustive list check SPC/BNF/Stockleys)

Mifamurtide	<p>Many interactions check carefully. High dose NSAIDs and ciclosporin must be avoided. Avoid steroids where possible as may dampen the immune response, but if other emetogenic chemotherapy due on the same day then risk vs benefit should be considered and lowest possible dose of steroids given. Not to be given on day of methotrexate. It is recommended to separate the administration times of mifamurtide and doxorubicin or other lipophilic medicinal products if used in the same chemotherapy regimen. Mifamurtide can be given within 1 hour of non-lipophilic forms of doxorubicin.</p>
-------------	---

DOSE MODIFICATIONS

Hepatic impairment

Mifamurtide

Caution should be used.

Continued monitoring of the kidney function is recommended if mifamurtide is used beyond completion of chemotherapy until all therapy is completed.

Renal impairment

Mifamurtide

Caution should be used.

Continued monitoring of the liver function is recommended if mifamurtide is used beyond completion of chemotherapy until all therapy is completed.

REFERENCES

1. SPC